Literature DB >> 2163236

N-methyl-D-aspartate antagonist reduces stroke size and regional glucose metabolism.

R Simon1, K Shiraishi.   

Abstract

Pharmacological inhibition of cell excitation during focal ischemia was studied in the rat middle cerebral artery occlusion model. The potent and selective N-methyl-D-aspartate antagonist CGS 19755, administered 5 minutes prior to or 5 minutes following permanent middle cerebral artery occlusion, caused a substantial decrease in infarct size, which was associated with reduction of postischemic cerebral glucose hypermetabolism. These data support a role for excitation-induced hypermetabolism in the pathogenesis of infarction following focal cerebrovascular occlusion.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2163236     DOI: 10.1002/ana.410270604

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  14 in total

Review 1.  Autoradiographic assessment of the effects of N-methyl-D-aspartate (NMDA) receptor antagonists in vivo.

Authors:  J McCulloch; L L Iversen
Journal:  Neurochem Res       Date:  1991-09       Impact factor: 3.996

Review 2.  Neuroprotection for ischemic stroke: past, present and future.

Authors:  Myron D Ginsberg
Journal:  Neuropharmacology       Date:  2008-03-04       Impact factor: 5.250

Review 3.  Clinical trials for cytoprotection in stroke.

Authors:  Lise A Labiche; James C Grotta
Journal:  NeuroRx       Date:  2004-01

Review 4.  Inducible glutamate oxaloacetate transaminase as a therapeutic target against ischemic stroke.

Authors:  Savita Khanna; Zachary Briggs; Cameron Rink
Journal:  Antioxid Redox Signal       Date:  2015-01-10       Impact factor: 8.401

5.  Src Family Kinases in Brain Edema After Acute Brain Injury.

Authors:  DaZhi Liu; Xiong Zhang; BeiLei Hu; Bradley P Ander
Journal:  Acta Neurochir Suppl       Date:  2016

6.  Competitive as well as uncompetitive N-methyl-D-aspartate receptor antagonists affect cortical neuronal morphology and cerebral glucose metabolism.

Authors:  R J Hargreaves; M Rigby; D Smith; R G Hill; L L Iversen
Journal:  Neurochem Res       Date:  1993-12       Impact factor: 3.996

7.  Reduction of CuZn-superoxide dismutase activity exacerbates neuronal cell injury and edema formation after transient focal cerebral ischemia.

Authors:  T Kondo; A G Reaume; T T Huang; E Carlson; K Murakami; S F Chen; E K Hoffman; R W Scott; C J Epstein; P H Chan
Journal:  J Neurosci       Date:  1997-06-01       Impact factor: 6.167

8.  Attenuation of focal cerebral ischemic injury in transgenic mice overexpressing CuZn superoxide dismutase.

Authors:  H Kinouchi; C J Epstein; T Mizui; E Carlson; S F Chen; P H Chan
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

9.  Pretreatment with a competitive NMDA antagonist D-CPPene attenuates focal cerebral infarction and brain swelling in awake rats.

Authors:  C K Park; J McCulloch; J K Kang; C R Choi
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

10.  CGS 19755 (Selfotel): A Novel Neuroprotective Agent Against CNS Injury.

Authors:  Miguel A Pérez-Pinzón; Gary K Steinberg
Journal:  CNS Drug Rev       Date:  1996-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.